Browse the evidence

GIPR antagonism reduces body weight in preclinical models by restoring leptin sensitivity, thereby reducing appetite.

Blocking GIP receptors can help obese individuals lose weight by making their bodies more sensitive to leptin, the hormone that signals fullness. This is currently only proven in animal models.

Sustained high-protein diets (HPD) exceeding 1.5 g/kg/day, particularly when consumed by athletes and bodybuilders, induce glomerular hyperfiltration and progressive glomerulosclerosis, leading to a rapid decline in kidney function and potential end-stage kidney disease.

If you are an athlete or bodybuilder, consuming protein levels significantly above 1.6 g/kg/day (often 3-4 g/kg/day) does not build more muscle but may accelerate kidney damage, especially if you have any underlying kidney issues. Monitor your kidney function regularly and consider reducing protein intake to the 1.6 g/kg/day range to maximize muscle gains while minimizing renal risk.

GLP-1 receptor agonists (semaglutide, tirzepatide) are effective for weight loss in the general population but demonstrate attenuated efficacy and unclear safety profiles specifically in breast cancer patients, particularly those receiving endocrine therapy.

If you have breast cancer and are taking hormonal therapy (like aromatase inhibitors), GLP-1 drugs like Semaglutide or Tirzepatide will likely help you lose weight, but not as much as they do for people without cancer. You should expect roughly half the weight loss seen in the general population. Discuss this with your oncologist, as safety data in your specific group is still being gathered.

Duodenal mucosal ablation (DMR) significantly reduces HbA1c in patients with Type 2 Diabetes, particularly those with high fasting glucose or insulin-requiring disease, by targeting the proximal small bowel to mimic the metabolic effects of bariatric surgery.

If you have Type 2 Diabetes and struggle to control your blood sugar with diet and medication, especially if you require insulin or have high fasting glucose, ask your doctor about Duodenal Mucosal Resurfacing (DMR). This is a minimally invasive endoscopic procedure that ablates a small section of your small intestine to improve how your body handles glucose. It is not a weight-loss surgery, but it can significantly lower your HbA1c and potentially reduce or eliminate your need for insulin. While it is a one-time procedure, it carries risks like stricture formation, so it is best considered for patients who have not responded to other treatments.

Roux-en-Y gastric bypass (RYGB) induces significant remission of Type 2 Diabetes (T2DM) and Systemic Arterial Hypertension (SAH) in obese patients, largely through neuroendocrine mechanisms involving GLP-1 and bile acids, independent of or in addition to weight loss.

For obese patients with difficult-to-control diabetes or hypertension, Roux-en-Y gastric bypass is a highly effective treatment that can lead to disease remission. This benefit is driven by hormonal changes in the gut (GLP-1 and bile acids) that improve metabolic control, not just by weight loss. While lifestyle changes are the first line of defense, they often fail to sustain control, making surgery a viable option for eligible candidates.

Generic public health messaging encouraging adults to 'eat less' or reduce caloric intake is ineffective and potentially harmful because it fails to provide actionable strategies, ignores complex social and environmental barriers, and can trigger negative psychological outcomes in vulnerable populations.

Stop telling people to 'eat less' or count calories, as this induces fear and confusion. Instead, provide specific, actionable instructions on how to increase nutrient-dense foods (like vegetables) to naturally crowd out calorie-dense options. Use trusted sources like healthcare providers to deliver these clear, behavior-based messages.

Calorie reduction messaging is counterproductive and potentially harmful for individuals with food insecurity or eating disorders, as it can reinforce distorted logic, rationalize harmful behaviors, or ignore survival priorities.

Do not use generic calorie reduction campaigns for food-insecure communities or individuals with eating disorders. For food-insecure groups, focus on access and quality, not restriction. For those with eating disorders, such messages can be dangerous and should be excluded or carefully managed by mental health professionals.

A persistently low fat-to-energy ratio (FER) and high carbohydrate-to-energy ratio (CER) diet is not significantly associated with obesity, diabetes, cardiovascular disease, or all-cause mortality after adjusting for social environment covariates.

Maintaining a diet lower in fat and higher in carbohydrates does not appear to increase your risk of obesity, diabetes, heart disease, or death, provided you account for social factors like income and urbanization. This challenges the idea that high-carb diets are inherently unhealthy.

Peak week strategies in non-drug-free bodybuilders, including supraphysiological anabolic steroid use, diuretics, and severe caloric/water restriction, fail to prevent significant losses in lean mass markers and resting metabolic rate.

If you are preparing for a physique competition using performance-enhancing drugs and extreme peak week strategies, be aware that these methods often fail to preserve lean muscle mass and metabolic rate. The combination of high-volume cardio, severe caloric restriction, and polypharmacy can lead to significant muscle loss despite the use of steroids. Individualize your protocol rather than copying a single coach's 'one-size-fits-all' approach, and prioritize muscle preservation over extreme dehydration tactics.

Adipose-specific overexpression of UCP1 via hADP promoter-modified plasmids induces thermogenesis and energy expenditure, leading to significant fat mass loss without lean mass loss in obese mice.

This research suggests that stimulating fat tissue to burn energy (thermogenesis) via a specific gene therapy could reduce fat mass without losing muscle. While promising in mice, this is not yet a human treatment. The key takeaway is that targeting energy expenditure in fat cells is a viable strategy for obesity, potentially avoiding the gut side effects of current drugs like GLP-1 agonists.

The ketone body β-hydroxybutyrate (βHB) inhibits glucose-induced GLP-1 secretion in enteroendocrine cells, with human jejunal enteroids showing sensitivity at much lower doses (10 mM) than murine cell lines (100 mM).

This research suggests that high concentrations of ketone bodies in the gut can suppress the release of GLP-1, a hormone that helps manage blood sugar and signals fullness. While this is a laboratory finding using human gut cells, it implies that metabolic states with high local ketone production (such as during fasting or specific dietary patterns) might alter how your body responds to carbohydrates by reducing this specific hormonal signal.

Intragastric balloons (IGBs) provide modest short-term weight loss (approx. 13% TBWL at 6 months) but are associated with higher adverse event rates and significant weight regain long-term, limiting their standalone efficacy.

IGBs can help you lose about 13% of your body weight in the first 6 months, but they are not a permanent solution. You will likely experience nausea and pain, and many people regain the weight after the balloon is removed. They are best used as a short-term tool to kickstart weight loss or as a bridge to surgery, combined with strict lifestyle changes.

GLP-1 receptor agonists (GLP-1RAs) do not increase the risk of adverse events compared to non-GLP-1RA antiobesity medications in patients who have undergone bariatric surgery.

If you have had bariatric surgery and are considering GLP-1 medications (like semaglutide or liraglutide) for weight regain, current data suggests they are not more likely to cause adverse events than older weight loss medications. However, the study notes that starting these medications more than 12 months after surgery is associated with a significantly lower risk of adverse events compared to starting them within the first year.

Tirzepatide is associated with a higher likelihood of gastrointestinal adverse events compared to other GLP-1 receptor agonists (semaglutide, dulaglutide, liraglutide, and exenatide).

If you take tirzepatide, expect gastrointestinal issues like nausea or vomiting more often than with other GLP-1 drugs. These are usually mild and go away, but they are the most common reason people stop the medication. Monitor your symptoms and report them.

Systems-oriented functional profiling (phenotypic/omics) and chemical fingerprinting of phytochemicals provide a more rational basis for evaluating plant-derived T2D pharmacotherapies than traditional target-centric approaches.

For those interested in plant-based approaches to diabetes, the scientific community is moving towards understanding how whole plant extracts work through multiple pathways rather than just one. This suggests that standardized, well-analyzed botanical preparations may offer benefits that single-molecule drugs do not, particularly in addressing the complex, multi-factorial nature of Type 2 Diabetes.

College students overwhelmingly perceive no-fat food preparations as healthier than those containing unsaturated or saturated fats, despite nutritional guidelines recommending unsaturated fats.

Stop avoiding fat. Choose foods with unsaturated fats (like olive oil, nuts, avocados) over no-fat options. The type of fat matters more for your health than simply removing fat from your diet.

Oral delivery of GLP-1 analogs (semaglutide, exenatide, dulaglutide) using liposomes containing tetraether lipids (TELs) and cell-penetrating peptides (CPPs) significantly increases cellular uptake in intestinal epithelial models compared to free peptides or conventional liposomes.

This research suggests a promising future where GLP-1 drugs (like Ozempic or Wegovy) could be taken orally using advanced liposome technology, potentially replacing injections. Currently, this is pre-clinical data showing high uptake in cell models, not a available product.

Acute L-arginine supplementation (6–8 g) taken 60–90 minutes before strength training provides no ergogenic effect on muscular endurance, peak torque, or resistance rate.

Do not take L-arginine specifically to boost your strength training performance. Taking 6-8 grams an hour before lifting does not increase your strength, endurance, or muscle growth compared to a placebo. While it may increase blood flow, this does not help you lift more weight or do more reps.

In patients with type 2 diabetes and baseline eGFR <80 mL/min/1.73 m2, intensive lifestyle intervention is associated with a slightly higher mean eGFR over 10 years compared to usual care, suggesting a potential benefit in preserving kidney function in this subgroup.

If your kidney function is already slightly reduced (eGFR <80), an intensive lifestyle program may help you maintain a slightly higher average kidney function level over 10 years compared to standard care. While it may not stop the decline entirely, it might offer a small protective benefit. Discuss this with your doctor to see if you are a candidate.

The doubly labeled water (DLW) method systematically overestimates energy expenditure differences when comparing low-carbohydrate diets to moderate-carbohydrate diets, likely due to isotopic fractionation and biosynthetic fluxes (e.g., de novo lipogenesis) that violate DLW assumptions.

If you are using the Doubly Labeled Water method to prove that low-carb diets burn more calories, be cautious. This study suggests the method may falsely show an increase due to how it handles isotopes during low-carb metabolism. Other rigorous measures (respiratory chambers, body composition changes) did not show this increase. Therefore, claims of a significant metabolic boost from low-carb diets based solely on DLW data may be overstated.

Compounded GLP-1 receptor agonists (semaglutide, tirzepatide) are widely marketed for weight loss in Colorado, but these products lack FDA approval for safety and efficacy, are often mislabeled as 'generic' or 'FDA-approved', and may contain unsafe additives like BPC-157 or unapproved salt forms.

Be aware that compounded GLP-1 drugs sold directly to consumers are not FDA-approved for safety or efficacy. They may contain impurities, incorrect doses, or unsafe additives like BPC-157. Marketing claims of 'FDA approval' or 'generic' status are misleading. Consult a healthcare provider to understand the risks and legal status of these products.

Subcutaneous administration of a semaglutide-rosuvastatin-lipid conjugate nanoparticle (SRLC NP) formulation significantly reduces body weight and improves liver function markers in high-fat diet-induced obese mice compared to conventional semaglutide or individual components.

This research describes a novel experimental nanoparticle formulation combining semaglutide with a statin-lipid conjugate. In obese mice, this specific formulation led to significant weight loss and liver health improvements compared to standard treatments. However, this is preclinical data; it is not a current treatment option for humans, and the safety and efficacy in people remain unproven.

Dihydromyricetin (DHM) supplementation improves insulin resistance and glucose tolerance in high-fat diet-induced mice by modulating gut microbiota to increase chenodeoxycholic acid (CDCA), which inhibits farnesoid X receptor (FXR) expression in intestinal L cells, thereby increasing glucagon gene (Gcg) mRNA expression and enhancing glucagon-like peptide-1 (GLP-1) secretion.

This research suggests that Dihydromyricetin (DHM), a compound found in plants like Ampelopsis grossedentata, may help improve insulin sensitivity and blood sugar control by changing gut bacteria to produce more beneficial bile acids (CDCA). This process boosts GLP-1, a hormone that helps regulate blood sugar. While this was shown in mice fed a high-fat diet, it points to the importance of gut health in metabolic function. For humans, this implies that dietary sources of DHM or gut-health-supporting strategies might be a complementary approach to managing insulin resistance, though human dosing and efficacy are not yet established.

Dysregulation of hypothalamic nuclei (specifically AgRP and POMC neurons in the arcuate nucleus) is a primary driver of obesity and type 2 diabetes through mechanisms involving insulin resistance, hyperphagia, and disrupted glucose sensing.

Metabolic diseases like obesity and diabetes are not just about willpower or peripheral fat storage; they involve critical signaling centers in the brain (the hypothalamus). When these signals (like leptin and insulin) are disrupted, it drives hunger and insulin resistance. This understanding supports the use of therapies that target these central pathways, such as GLP-1 receptor agonists, to help restore metabolic balance.